{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:12:14Z","timestamp":1794651134331,"version":"4.9.1"},"reference-count":251,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41581-026-01117-6","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:23:20Z","timestamp":1788528200000},"page":"784-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-5700","authenticated-orcid":false,"given":"Radica Z.","family":"Alicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"1117_CR1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","volume":"406","author":"GBD 2023 Chronic","year":"2025","unstructured":"GBD 2023 Chronic Kidney Disease CollaboratorsGlobal, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461\u20132482 (2025).","journal-title":"Lancet"},{"key":"1117_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort, R. T. et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382, 339\u2013352 (2013).","journal-title":"Lancet"},{"key":"1117_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski, J., Floege, J., Fliser, D., B\u00f6hm, M. & Marx, N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143, 1157\u20131172 (2021).","journal-title":"Circulation"},{"key":"1117_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1159\/000528560","volume":"53","author":"X Li","year":"2022","unstructured":"Li, X. & Lindholm, B. Cardiovascular risk prediction in chronic kidney disease. Am. J. Nephrol. 53, 730\u2013739 (2022).","journal-title":"Am. J. Nephrol."},{"key":"1117_CR5","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/ndt\/gfaf020","volume":"40","author":"C Zoccali","year":"2025","unstructured":"Zoccali, C. et al. The autonomic nervous system and inflammation in chronic kidney disease. Nephrol. Dial. Transpl. 40, 1470\u20131482 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2180373","volume":"2018","author":"S Mihai","year":"2018","unstructured":"Mihai, S. et al. Inflammation-Related mechanisms in chronic kidney disease prediction, progression, and outcome. J. Immunol. Res. 2018, 2180373 (2018).","journal-title":"J. Immunol. Res."},{"key":"1117_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2215\/CJN.13121215","volume":"11","author":"RL Amdur","year":"2016","unstructured":"Amdur, R. L. et al. Inflammation and progression of CKD: the CRIC study. Clin. J. Am. Soc. Nephrol. 11, 1546\u20131556 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1117_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00398.x","volume":"68","author":"M Tonelli","year":"2005","unstructured":"Tonelli, M., Sacks, F., Pfeffer, M., Jhangri, G. S. & Curhan, G. Cholesterol, recurrent events trial I. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 68, 237\u2013245 (2005).","journal-title":"Kidney Int."},{"key":"1117_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle, K. R. et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 102, 248\u2013260 (2022).","journal-title":"Kidney Int."},{"key":"1117_CR10","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","volume":"25","author":"D Furman","year":"2019","unstructured":"Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25, 1822\u20131832 (2019).","journal-title":"Nat. Med."},{"key":"1117_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","volume":"15","author":"L Ferrucci","year":"2018","unstructured":"Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 15, 505\u2013522 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1117_CR12","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2215\/CJN.03500412","volume":"7","author":"J Gupta","year":"2012","unstructured":"Gupta, J. et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin. J. Am. Soc. Nephrol. 7, 1938\u20131946 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1117_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0272-6386(03)00408-6","volume":"42","author":"JF Navarro","year":"2003","unstructured":"Navarro, J. F., Mora, C., Maca, M. & Garca, J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am. J. Kidney Dis. 42, 53\u201361 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000042700.48769.59","volume":"107","author":"MG Shlipak","year":"2003","unstructured":"Shlipak, M. G. et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107, 92 (2003).","journal-title":"Circulation"},{"key":"1117_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/ndt\/gfq471","volume":"26","author":"A Upadhyay","year":"2011","unstructured":"Upadhyay, A. et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol. Dial. Transpl. 26, 920\u2013926 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2012.02.335","volume":"60","author":"JS Hiramoto","year":"2012","unstructured":"Hiramoto, J. S. et al. Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Kidney Dis. 60, 225\u2013232 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","volume":"55","author":"P Stenvinkel","year":"1999","unstructured":"Stenvinkel, P. et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 55, 1899\u20131911 (1999).","journal-title":"Kidney Int."},{"key":"1117_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2215\/CJN.08660813","volume":"9","author":"MI Yilmaz","year":"2014","unstructured":"Yilmaz, M. I. et al. The relationship between IL-10 levels and cardiovascular events in patients with CKD. Clin. J. Am. Soc. Nephrol. 9, 1207\u20131216 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1117_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1053\/j.ajkd.2009.02.008","volume":"53","author":"S Snaedal","year":"2009","unstructured":"Snaedal, S. et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am. J. Kidney Dis. 53, 1024\u20131033 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrneph.2011.2","volume":"7","author":"CL Meuwese","year":"2011","unstructured":"Meuwese, C. L., Stenvinkel, P., Dekker, F. W. & Carrero, J. J. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat. Rev. Nephrol. 7, 166\u2013176 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"1117_CR21","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","volume":"45","author":"F Mazhar","year":"2024","unstructured":"Mazhar, F. et al. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease. Eur. Heart J. 45, 4719\u20134730 (2024).","journal-title":"Eur. Heart J."},{"key":"1117_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1053\/j.ajkd.2025.04.011","volume":"86","author":"F Mazhar","year":"2025","unstructured":"Mazhar, F. et al. Systemic inflammation and the risks of adverse kidney outcomes in adults with atherosclerotic cardiovascular disease. Am. J. Kidney Dis. 86, 314\u2013323.e1 (2025).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR23","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.2215\/CJN.00710111","volume":"6","author":"J Bazeley","year":"2011","unstructured":"Bazeley, J. et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 2452\u20132461 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1117_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/ndt\/gfq557","volume":"26","author":"CL Meuwese","year":"2011","unstructured":"Meuwese, C. L. et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-\u03b1 are similarly associated with survival in haemodialysis patients. Nephrol. Dial. Transpl. 26, 1313\u20131318 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ajkd.2003.07.016","volume":"42","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh, K., Ikizler, T. A., Block, G., Avram, M. M. & Kopple, J. D. Malnutrition\u2013inflammation complex syndrome in dialysis patients: causes and consequences. Am. J. Kidney Dis. 42, 864\u2013881 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.ajkd.2006.03.047","volume":"48","author":"K Kalantar-Zadeh","year":"2006","unstructured":"Kalantar-Zadeh, K., Brennan, M. L. & Hazen, S. L. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am. J. Kidney Dis. 48, 59\u201368 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR27","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2215\/CJN.03100315","volume":"10","author":"R Poesen","year":"2015","unstructured":"Poesen, R. et al. Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with CKD. Clin. J. Am. Soc. Nephrol. 10, 1525\u20131533 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1117_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/ki.2009.503","volume":"77","author":"DV Barreto","year":"2010","unstructured":"Barreto, D. V. et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 77, 550\u2013556 (2010).","journal-title":"Kidney Int."},{"key":"1117_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1523-1755.2005.00455.x","volume":"68","author":"V Menon","year":"2005","unstructured":"Menon, V. et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 68, 766\u2013772 (2005).","journal-title":"Kidney Int."},{"key":"1117_CR30","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1093\/ndt\/gfn341","volume":"23","author":"S Vickery","year":"2008","unstructured":"Vickery, S. et al. Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population. Nephrol. Dial. Transpl. 23, 3546\u20133553 (2008).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.ajkd.2005.09.014","volume":"47","author":"H Honda","year":"2006","unstructured":"Honda, H. et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney Dis. 47, 139\u2013148 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR32","first-page":"S0735","volume":"29","author":"GA Mensah","year":"2025","unstructured":"Mensah, G. A. et al. Inflammation and cardiovascular disease: 2025 ACC Scientific Statement: a report of the American College of Cardiology. J. Am. Coll. Cardiol. 29, S0735\u2013S1097 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1117_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/eurheartj\/ehaf919","volume":"47","author":"F Mach","year":"2026","unstructured":"Mach, F., Roeters van Lennep, J. E. & Koskinas, K. C. The \u201810 commandments\u2019 for the 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. 47, 658\u2013659 (2026).","journal-title":"Eur. Heart J."},{"key":"1117_CR34","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001457","volume":"153","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal, R. S. et al. ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 153, e1154\u2013e1276 (2026).","journal-title":"Circulation"},{"key":"1117_CR35","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1681\/ASN.2006080910","volume":"17","author":"C Zoccali","year":"2006","unstructured":"Zoccali, C., Tripepi, G. & Mallamaci, F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J. Am. Soc. Nephrol. 17, S169\u2013S173 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124772","volume":"10","author":"J Gupta","year":"2015","unstructured":"Gupta, J. et al. Association between inflammation and cardiac geometry in chronic kidney disease: findings from the CRIC study. PLoS ONE 10, e0124772 (2015).","journal-title":"PLoS ONE"},{"key":"1117_CR37","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1093\/ndt\/gfr081","volume":"26","author":"MI Yilmaz","year":"2011","unstructured":"Yilmaz, M. I. et al. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol. Dial. Transpl. 26, 3537\u20133543 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR38","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1161\/01.ATV.0000235691.84430.86","volume":"26","author":"C Herder","year":"2006","unstructured":"Herder, C. et al. Chemokines and incident coronary heart disease: results from the MONICA\/KORA Augsburg case-cohort study, 1984\u20132002. Arterioscler. Thromb. Vasc. Biol. 26, 2147\u20132152 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1117_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.123.064974","volume":"149","author":"S Prapiadou","year":"2024","unstructured":"Prapiadou, S. et al. Proteogenomic data integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis. Circulation 149, 669\u2013683 (2024).","journal-title":"Circulation"},{"key":"1117_CR40","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/j.ajkd.2016.07.022","volume":"68","author":"FR Mc Causland","year":"2016","unstructured":"Mc Causland, F. R. et al. C-reactive protein and risk of ESRD: results from the trial to reduce cardiovascular events with aranesp therapy (TREAT). Am. J. Kidney Dis. 68, 873\u2013881 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR41","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.2337\/dc22-0866","volume":"45","author":"A Koshino","year":"2022","unstructured":"Koshino, A. et al. Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS. Diabetes Care 45, 2644\u20132652 (2022).","journal-title":"Diabetes Care"},{"key":"1117_CR42","first-page":"79","volume":"74","author":"TH Wu","year":"1996","unstructured":"Wu, T. H., Wu, S. C., Huang, T. P., Yu, C. L. & Tsai, C. Increased excretion of tumor necrosis factor alpha and interleukin 1 beta in urine from patients with IgA nephropathy and Sch\u00f6nlein-Henoch purpura. Nephron 74, 79\u201388 (1996).","journal-title":"Nephron"},{"key":"1117_CR43","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/sj.ki.5000302","volume":"69","author":"YM Chen","year":"2006","unstructured":"Chen, Y. M., Lin, S. L., Chiang, W. C., Wu, K. D. & Tsai, T. J. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 69, 1410\u20131415 (2006).","journal-title":"Kidney Int."},{"key":"1117_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1081\/JDI-120021156","volume":"25","author":"T Morii","year":"2003","unstructured":"Morii, T. et al. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases. Ren. Fail. 25, 439\u2013444 (2003).","journal-title":"Ren. Fail."},{"key":"1117_CR45","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1046\/j.1523-1755.2002.00677.x","volume":"62","author":"MJ Sarnak","year":"2002","unstructured":"Sarnak, M. J. et al. Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int. 62, 2208\u20132215 (2002).","journal-title":"Kidney Int."},{"key":"1117_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ahj.2019.06.019","volume":"216","author":"EL Fu","year":"2019","unstructured":"Fu, E. L. et al. High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients. Am. Heart J. 216, 20\u201329 (2019).","journal-title":"Am. Heart J."},{"key":"1117_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2215\/CJN.0000000857","volume":"21","author":"KR Tuttle","year":"2026","unstructured":"Tuttle, K. R. et al. A real-world cohort study of the risks of kidney failure and death in diabetes. Clin. J. Am. Soc. Nephrol. 21, 83\u201394 (2026).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1117_CR48","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1097\/01.ASN.0000146422.45434.35","volume":"15","author":"L Fried","year":"2004","unstructured":"Fried, L. et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J. Am. Soc. Nephrol. 15, 3184\u20133191 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/eurjpc\/zwaf779","volume":"33","author":"OJ Agboola","year":"2026","unstructured":"Agboola, O. J. et al. The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis. Eur. J. Prev. Cardiol. 33, 718\u2013728 (2026).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1117_CR50","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/ndt\/gfn543","volume":"24","author":"BD Bradbury","year":"2009","unstructured":"Bradbury, B. D. et al. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol. Dial. Transpl. 24, 919\u2013925 (2009).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.xkme.2020.01.007","volume":"2","author":"A Karaboyas","year":"2020","unstructured":"Karaboyas, A. et al. Inflammation and erythropoiesis-stimulating agent response in hemodialysis patients: a self-matched longitudinal study of anemia management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Med. 2, 286\u2013296 (2020).","journal-title":"Kidney Med."},{"key":"1117_CR52","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/sdi.12107","volume":"26","author":"CP Kovesdy","year":"2013","unstructured":"Kovesdy, C. P. How can erythropoietin-stimulating agent use be reduced in chronic dialysis patients?: can reduction of inflammation improve ESA dose response? Semin. Dial. 26, 540\u2013542 (2013).","journal-title":"Semin. Dial."},{"key":"1117_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.jrn.2013.01.001","volume":"23","author":"JJ Carrero","year":"2013","unstructured":"Carrero, J. J. et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J. Ren. Nutr. 23, 77\u201390 (2013).","journal-title":"J. Ren. Nutr."},{"key":"1117_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95185","volume":"2","author":"SM Deger","year":"2017","unstructured":"Deger, S. M. et al. Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients. JCI Insight 2, e95185 (2017).","journal-title":"JCI Insight"},{"key":"1117_CR55","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrneph.2014.112","volume":"10","author":"XH Wang","year":"2014","unstructured":"Wang, X. H. & Mitch, W. E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 10, 504\u2013516 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"1117_CR56","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/ndt\/gfw104","volume":"31","author":"S Snaedal","year":"2016","unstructured":"Snaedal, S. Dialysis modality and nutritional status are associated with variability of inflammatory markers. Nephrol. Dial. Transpl. 31, 1320\u20131327 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR57","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/ndt\/15.7.953","volume":"15","author":"P Stenvinkel","year":"2000","unstructured":"Stenvinkel, P. et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transpl. 15, 953\u2013608 (2000).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR58","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh, K., Block, G., Humphreys, M. H. & Kopple, J. D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 63, 793\u2013808 (2003).","journal-title":"Kidney Int."},{"key":"1117_CR59","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ncpneph0834","volume":"4","author":"M Rambod","year":"2008","unstructured":"Rambod, M., Kovesdy, C. & Kalantar-Zadeh, K. Malnutrition\u2013Inflammation Score for risk stratification of patients with CKD: is it the promised gold standard?Nat. Rev. Nephrol. 4, 354\u2013355 (2008).","journal-title":"Nat. Rev. Nephrol."},{"key":"1117_CR60","doi-asserted-by":"publisher","first-page":"A33","DOI":"10.1016\/j.jacc.2006.08.011","volume":"48","author":"P Libby","year":"2006","unstructured":"Libby, P. & Ridker, P. M. Inflammation and atherothrombosis: from population biology and bench research to clinical practice. J. Am. Coll. Cardiol. 48, A33\u2013A46 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1117_CR61","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s42255-022-00674-x","volume":"4","author":"O Bondareva","year":"2022","unstructured":"Bondareva, O. et al. Single-cell profiling of vascular endothelial cells reveals progressive organ-specific vulnerabilities during obesity. Nat. Metab. 4, 1591\u20131610 (2022).","journal-title":"Nat. Metab."},{"key":"1117_CR62","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/CIRCRESAHA.122.321749","volume":"132","author":"C Zoccali","year":"2023","unstructured":"Zoccali, C. & Mallamaci, F. Innate immunity system in patients with cardiovascular and kidney disease. Circ. Res. 132, 915\u2013932 (2023).","journal-title":"Circ. Res."},{"key":"1117_CR63","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41581-020-0272-y","volume":"16","author":"C Kurts","year":"2020","unstructured":"Kurts, C., Ginhoux, F. & Panzer, U. Kidney dendritic cells: fundamental biology and functional roles in health and disease. Nat. Rev. Nephrol. 16, 391\u2013407 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1117_CR64","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.imlet.2017.01.011","volume":"183","author":"YH Wang","year":"2017","unstructured":"Wang, Y. H. & Zhang, Y. G. Kidney and innate immunity. Immunol. Lett. 183, 73\u201378 (2017).","journal-title":"Immunol. Lett."},{"key":"1117_CR65","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrneph.2014.91","volume":"10","author":"JC Leemans","year":"2014","unstructured":"Leemans, J. C., Kors, L., Anders, H. J. & Florquin, S. Pattern recognition receptors and the inflammasome in kidney disease. Nat. Rev. Nephrol. 10, 398\u2013414 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"1117_CR66","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"SCW Tang","year":"2020","unstructured":"Tang, S. C. W. & Yiu, W. H. Innate immunity in diabetic kidney disease. Nat. Rev. Nephrol. 16, 206\u2013222 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1117_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/BOR.0000000000000887","volume":"35","author":"R Bhargava","year":"2023","unstructured":"Bhargava, R., Li, H. & Tsokos, G. C. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr. Opin. Rheumatol. 35, 107\u2013116 (2023).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1117_CR68","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-023-00786-x","volume":"20","author":"GC Tsokos","year":"2024","unstructured":"Tsokos, G. C. et al. The immunoregulatory roles of non-haematopoietic cells in the kidney. Nat. Rev. Nephrol. 20, 206\u2013217 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1117_CR69","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/ndt\/gft446","volume":"29","author":"M Lin","year":"2014","unstructured":"Lin, M. & Tang, S. C. Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrol. Dial. Transpl. 29, 746\u2013754 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cyto.2015.02.025","volume":"74","author":"D De Nardo","year":"2015","unstructured":"De Nardo, D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine 74, 181\u2013189 (2015).","journal-title":"Cytokine"},{"key":"1117_CR71","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ndt\/15.5.574","volume":"15","author":"JE Scherberich","year":"2000","unstructured":"Scherberich, J. E. & Nockher, W. A. Blood monocyte phenotypes and soluble endotoxin receptor CD14 in systemic inflammatory diseases and patients with chronic renal failure. Nephrol. Dial. Transpl. 15, 574\u2013578 (2000).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR72","doi-asserted-by":"publisher","first-page":"9729","DOI":"10.1074\/jbc.M113.453266","volume":"288","author":"DRE Ranoa","year":"2013","unstructured":"Ranoa, D. R. E., Kelley, S. L. & Tapping, R. I. Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J. Biol. Chem. 288, 9729\u20139741 (2013).","journal-title":"J. Biol. Chem."},{"key":"1117_CR73","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1681\/ASN.2010111210","volume":"23","author":"M Lin","year":"2012","unstructured":"Lin, M. et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol. 23, 86\u2013102 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR74","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/01.ASN.0000065100.17349.CA","volume":"14","author":"T Wendt","year":"2003","unstructured":"Wendt, T. et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 14, 1383\u20131395 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR75","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/sj.ki.5002386","volume":"106","author":"H Noh","year":"2007","unstructured":"Noh, H. & King, G. L. The role of protein kinase C activation in diabetic nephropathy. Kidney Int. Suppl. 106, S49\u2013S53 (2007).","journal-title":"Kidney Int. Suppl."},{"key":"1117_CR76","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/ndt\/gfs579","volume":"28","author":"RL Meek","year":"2013","unstructured":"Meek, R. L. et al. Glomerular cell death and inflammation with high-protein diet and diabetes. Nephrol. Dial. Transpl. 28, 1711\u20131720 (2013).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR77","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000154470","volume":"29","author":"KR Tuttle","year":"2009","unstructured":"Tuttle, K. R., Anderberg, R. J., Cooney, S. K. & Meek, R. L. Oxidative stress mediates protein kinase C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet. Am. J. Nephrol. 29, 171\u2013180 (2009).","journal-title":"Am. J. Nephrol."},{"key":"1117_CR78","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2337\/db08-1328","volume":"58","author":"CC Berthier","year":"2009","unstructured":"Berthier, C. C. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469\u2013477 (2009).","journal-title":"Diabetes"},{"key":"1117_CR79","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/labinvest.2014.163","volume":"95","author":"RJ Anderberg","year":"2015","unstructured":"Anderberg, R. J. et al. Serum amyloid A and inflammation in diabetic kidney disease and podocytes. Lab. Invest. 95, 250\u2013262 (2015).","journal-title":"Lab. Invest."},{"key":"1117_CR80","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1681\/ASN.V1191656","volume":"11","author":"N Tanji","year":"2000","unstructured":"Tanji, N. et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11, 1656\u20131666 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR81","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.kint.2019.01.014","volume":"96","author":"SR Mulay","year":"2019","unstructured":"Mulay, S. R. Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. Kidney Int. 96, 58\u201366 (2019).","journal-title":"Kidney Int."},{"key":"1117_CR82","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00395-017-0663-9","volume":"113","author":"D Liu","year":"2017","unstructured":"Liu, D., Zeng, X., Li, X., Mehta, J. L. & Wang, X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic. Res. Cardiol. 113, 5 (2017).","journal-title":"Basic. Res. Cardiol."},{"key":"1117_CR83","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1681\/ASN.2015060676","volume":"27","author":"K Shahzad","year":"2016","unstructured":"Shahzad, K. Caspase-1, but not caspase-3, promotes diabetic nephropathy. J. Am. Soc. Nephrol. 27, 2270\u20132275 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR84","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.kint.2022.06.010","volume":"102","author":"K Shahzad","year":"2022","unstructured":"Shahzad, K. et al. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. Kidney Int. 102, 766\u2013779 (2022).","journal-title":"Kidney Int."},{"key":"1117_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev.pharmtox.48.113006.094606","volume":"48","author":"K Takeda","year":"2008","unstructured":"Takeda, K., Noguchi, T., Naguro, I. & Ichijo, H. Apoptosis signal-regulating kinase 1 in stress and immune response. Annu. Rev. Pharmacol. Toxicol. 48, 199\u2013225 (2008).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1117_CR86","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1007\/s11010-025-05330-y","volume":"480","author":"D Thakur","year":"2025","unstructured":"Thakur, D. et al. Updated insights on ASK1 signaling: mechanisms, regulation, and therapeutic potential in diseases. Mol. Cell Biochem. 480, 5267\u20135296 (2025).","journal-title":"Mol. Cell Biochem."},{"key":"1117_CR87","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1172\/JCI99768","volume":"128","author":"JT Liles","year":"2018","unstructured":"Liles, J. T. et al. ASK1 contributes to fibrosis and dysfunction in models of kidney disease. J. Clin. Invest. 128, 4485\u20134500 (2018).","journal-title":"J. Clin. Invest."},{"key":"1117_CR88","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2017.03.003","volume":"37","author":"E Feigerlov\u00e1","year":"2017","unstructured":"Feigerlov\u00e1, E. & Battaglia-Hsu, S. F. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor. Rev. 37, 57\u201365 (2017).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1117_CR89","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","volume":"128","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. & Rane, M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ. Res. 128, 1728\u20131746 (2021).","journal-title":"Circ. Res."},{"key":"1117_CR90","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18, 773\u2013789 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1117_CR91","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1189\/jlb.1105674","volume":"80","author":"S Rose-John","year":"2006","unstructured":"Rose-John, S., Scheller, J., Elson, G. & Jones, S. A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80, 227\u2013236 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"1117_CR92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000059327","volume":"8","author":"I Coletta","year":"2000","unstructured":"Coletta, I. et al. Selective induction of MCP-1 in human mesangial cells by the IL-6\/sIL-6R complex. Exp. Nephrol. 8, 37\u201343 (2000).","journal-title":"Exp. Nephrol."},{"key":"1117_CR93","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1681\/ASN.2007070744","volume":"19","author":"Y Nechemia-Arbely","year":"2008","unstructured":"Nechemia-Arbely, Y. et al. IL-6\/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 19, 1106\u20131115 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR94","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.bbrc.2013.05.046","volume":"435","author":"DI Kim","year":"2013","unstructured":"Kim, D. I. & Park, S. H. Sequential signaling cascade of IL-6 and PGC-1\u03b1 is involved in high glucose-induced podocyte loss and growth arrest. Biochem. Biophys. Res. Commun. 435, 702\u2013707 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1117_CR95","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.kint.2022.10.008","volume":"103","author":"JR Privratsky","year":"2023","unstructured":"Privratsky, J. R. et al. A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. Kidney Int. 103, 514\u2013528 (2023).","journal-title":"Kidney Int."},{"key":"1117_CR96","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.7150\/thno.32352","volume":"9","author":"W Chen","year":"2019","unstructured":"Chen, W. et al. Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation. Theranostics 9, 3980\u20133991 (2019).","journal-title":"Theranostics"},{"key":"1117_CR97","doi-asserted-by":"publisher","first-page":"F762","DOI":"10.1152\/ajprenal.00181.2005","volume":"290","author":"MB Marrero","year":"2006","unstructured":"Marrero, M. B., Banes-Berceli, A. K., Stern, D. M. & Eaton, D. C. Role of the JAK\/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F762\u2013F768 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1117_CR98","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","volume":"22","author":"P Roy","year":"2022","unstructured":"Roy, P., Orecchioni, M. & Ley, K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. 22, 251\u2013265 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1117_CR99","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.immuni.2013.06.009","volume":"38","author":"P Libby","year":"2013","unstructured":"Libby, P., Lichtman, A. H. & Hansson, G. K. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38, 1092\u20131104 (2013).","journal-title":"Immunity"},{"key":"1117_CR100","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCRESAHA.118.311098","volume":"124","author":"P Libby","year":"2019","unstructured":"Libby, P., Pasterkamp, G., Crea, F. & Jang, I. K. Reassessing the mechanisms of acute coronary syndromes. Circ. Res. 124, 150\u2013160 (2019).","journal-title":"Circ. Res."},{"key":"1117_CR101","first-page":"2525","volume":"117","author":"P Libby","year":"2021","unstructured":"Libby, P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc. Res. 117, 2525\u20132536 (2021).","journal-title":"Cardiovasc. Res."},{"key":"1117_CR102","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685\u20131695 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR103","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1139\/cjpp-2016-0664","volume":"95","author":"V Rai","year":"2017","unstructured":"Rai, V. & Agrawal, D. K. The role of damage- and pathogen-associated molecular patterns in inflammation-mediated vulnerability of atherosclerotic plaques. Can. J. Physiol. Pharmacol. 95, 1245\u20131253 (2017).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"1117_CR104","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2022.04.011","volume":"350","author":"C Roesner","year":"2022","unstructured":"Roesner, C. et al. Differences of inflammatory cytokine profile in patients with vulnerable plaque: a coronary CTA study. Atherosclerosis 350, 25\u201332 (2022).","journal-title":"Atherosclerosis"},{"key":"1117_CR105","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.014959","volume":"16","author":"H Yuki","year":"2023","unstructured":"Yuki, H. et al. Coronary inflammation and plaque vulnerability: a coronary computed tomography and optical coherence tomography study. Circ. Cardiovasc. Imaging 16, e014959 (2023).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"1117_CR106","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","volume":"25","author":"DM Fernandez","year":"2019","unstructured":"Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 25, 1576\u20131588 (2019).","journal-title":"Nat. Med."},{"key":"1117_CR107","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nri2873","volume":"10","author":"GY Chen","year":"2010","unstructured":"Chen, G. Y. & Nu\u00f1ez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826\u2013837 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1117_CR108","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yjmcc.2018.06.001","volume":"121","author":"KH Simons","year":"2018","unstructured":"Simons, K. H. et al. The protective role of Toll-like receptor 3 and type-I interferons in the pathophysiology of vein graft disease. J. Mol. Cell Cardiol. 121, 16\u201324 (2018).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1117_CR109","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1053-2498(03)00106-2","volume":"23","author":"EJ Birks","year":"2004","unstructured":"Birks, E. J. et al. Increased Toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J. Heart Lung Transpl. 23, 228\u2013235 (2004).","journal-title":"J. Heart Lung Transpl."},{"key":"1117_CR110","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","volume":"558","author":"X Que","year":"2018","unstructured":"Que, X. et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558, 301\u2013306 (2018).","journal-title":"Nature"},{"key":"1117_CR111","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.apjtm.2016.03.021","volume":"9","author":"H Chen","year":"2016","unstructured":"Chen, H., Zhang, R. Q., Wei, X. G., Ren, X. M. & Gao, X. Q. Mechanism of TLR-4\/NF-\u03baB pathway in myocardial ischemia reperfusion injury of mouse. Asian Pac. J. Trop. Med. 9, 503\u2013507 (2016).","journal-title":"Asian Pac. J. Trop. Med."},{"key":"1117_CR112","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","volume":"21","author":"S Toldo","year":"2024","unstructured":"Toldo, S. & Abbate, A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat. Rev. Cardiol. 21, 219\u2013237 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1117_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00167","volume":"8","author":"A Chevriaux","year":"2020","unstructured":"Chevriaux, A. et al. Cathepsin B is required for NLRP3 inflammasome activation in macrophages, through NLRP3 interaction. Front. Cell Dev. Biol. 8, 167 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1117_CR114","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger, P. The danger model: a renewed sense of self. Science 296, 301\u2013305 (2002).","journal-title":"Science"},{"key":"1117_CR115","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/0008-8749(89)90095-6","volume":"122","author":"H Loppnow","year":"1989","unstructured":"Loppnow, H. & Libby, P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol. 122, 493\u2013503 (1989).","journal-title":"Cell Immunol."},{"key":"1117_CR116","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1111\/bph.12713","volume":"171","author":"D Qu","year":"2014","unstructured":"Qu, D., Liu, J., Lau, C. W. & Huang, Y. IL-6 in diabetes and cardiovascular complications. Br. J. Pharmacol. 171, 3595\u20133603 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"1117_CR117","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.cardfail.2015.04.014","volume":"21","author":"B Butts","year":"2015","unstructured":"Butts, B., Gary, R. A., Dunbar, S. B. & Butler, J. The importance of NLRP3 inflammasome in heart failure. J. Card. Fail. 21, 586\u2013593 (2015).","journal-title":"J. Card. Fail."},{"key":"1117_CR118","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","volume":"126","author":"A Abbate","year":"2020","unstructured":"Abbate, A. et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 126, 1260\u20131280 (2020).","journal-title":"Circ. Res."},{"key":"1117_CR119","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.jacc.2014.01.014","volume":"63","author":"IM Seropian","year":"2014","unstructured":"Seropian, I. M., Toldo, S., Van Tassell, B. W. & Abbate, A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J. Am. Coll. Cardiol. 63, 1593\u20131603 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1117_CR120","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.123.321637","volume":"132","author":"AR Tall","year":"2023","unstructured":"Tall, A. R. & Bornfeldt, K. E. Inflammasomes and atherosclerosis: a mixed picture. Circ. Res. 132, 1505\u20131520 (2023).","journal-title":"Circ. Res."},{"key":"1117_CR121","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1749-6632.2001.tb03939.x","volume":"947","author":"L Robbie","year":"2001","unstructured":"Robbie, L. & Libby, P. Inflammation and atherothrombosis. Ann. N. Y. Acad. Sci. 947, 167\u2013179 (2001).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1117_CR122","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2024.07.013","volume":"129","author":"L Liberale","year":"2024","unstructured":"Liberale, L. et al. Plasma levels of myeloperoxidase and resistin independently predict mortality in dialysis patients. Eur. J. Intern. Med. 129, 87\u201392 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"1117_CR123","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1053\/j.ajkd.2009.06.022","volume":"54","author":"DS Raj","year":"2009","unstructured":"Raj, D. S. et al. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am. J. Kidney Dis. 54, 1072\u20131080 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR124","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1053\/j.ajkd.2009.06.028","volume":"54","author":"DS Raj","year":"2009","unstructured":"Raj, D. S., Shah, V. O., Rambod, M., Kovesdy, C. P. & Kalantar-Zadeh, K. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am. J. Kidney Dis. 54, 1062\u20131071 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR125","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/ndt\/gfh143","volume":"19","author":"K Kalantar-Zadeh","year":"2004","unstructured":"Kalantar-Zadeh, K., Kopple, J. D., Humphreys, M. H. & Block, G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol. Dial. Transpl. 19, 1507\u20131519 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR126","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0272-6386(03)00915-6","volume":"242","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh, K. et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am. J. Kidney Dis. 242, 761\u2013773 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR127","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1681\/ASN.2018121231","volume":"30","author":"GM Chertow","year":"2019","unstructured":"Chertow, G. M. et al. Effects of selonsertib in patients with diabetic kidney disease. J. Am. Soc. Nephrol. 30, 1980\u20131990 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR128","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1681\/ASN.0000000000000444","volume":"35","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. Selonsertib in patients with diabetic kidney disease: a phase 2b randomized active run-in clinical trial. J. Am. Soc. Nephrol. 35, 1726\u20131736 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR129","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","volume":"59","author":"FC Brosius","year":"2016","unstructured":"Brosius, F. C., Tuttle, K. R. & Kretzler, M. JAK inhibition in the treatment of diabetic kidney disease. Diabetologia 59, 1624\u20131627 (2016).","journal-title":"Diabetologia"},{"key":"1117_CR130","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle, K. R. et al. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol. Dial. Transpl. 33, 1950\u20131959 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR131","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05237388 (2026)."},{"key":"1117_CR132","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2337\/db06-0891","volume":"56","author":"M Meier","year":"2006","unstructured":"Meier, M. et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 56, 346\u2013354 (2006).","journal-title":"Diabetes"},{"key":"1117_CR133","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","volume":"28","author":"KR Tuttle","year":"2005","unstructured":"Tuttle, K. R. et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28, 2686\u20132690 (2005).","journal-title":"Diabetes Care"},{"key":"1117_CR134","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2215\/CJN.00840207","volume":"2","author":"KR Tuttle","year":"2006","unstructured":"Tuttle, K. R., McGill, J. B., Haney, D. J., Lin, T. E. & Anderson, P. W. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin. J. Am. Soc. Nephrol. 2, 631\u2013636 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1117_CR135","doi-asserted-by":"publisher","first-page":"i19","DOI":"10.1093\/ndt\/gft224","volume":"29","author":"C Zoja","year":"2014","unstructured":"Zoja, C., Benigni, A. & Remuzzi, G. The Nrf2 pathway in the progression of renal disease. Nephrol. Dial. Transpl. 29, i19\u2013i24 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR136","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000475890","volume":"45","author":"M Nezu","year":"2017","unstructured":"Nezu, M., Suzuki, N. & Yamamoto, M. Targeting the KEAP1-NRF2 system to prevent kidney disease progression. Am. J. Nephrol. 45, 473\u2013483 (2017).","journal-title":"Am. J. Nephrol."},{"key":"1117_CR137","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1105351","volume":"365","author":"PE Pergola","year":"2011","unstructured":"Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327\u2013336 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR138","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","volume":"369","author":"D de Zeeuw","year":"2013","unstructured":"de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492\u20132503 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR139","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000362906","volume":"39","author":"MP Chin","year":"2014","unstructured":"Chin, M. P. et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am. J. Nephrol. 39, 499\u2013508 (2014).","journal-title":"Am. J. Nephrol."},{"key":"1117_CR140","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","volume":"20","author":"MP Chin","year":"2014","unstructured":"Chin, M. P. et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J. Card. Fail. 20, 953\u2013958 (2014).","journal-title":"J. Card. Fail."},{"key":"1117_CR141","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","volume":"5","author":"M Nangaku","year":"2020","unstructured":"Nangaku, M. et al. Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI Study). Kidney Int. Rep. 5, 879\u2013890 (2020).","journal-title":"Kidney Int. Rep."},{"key":"1117_CR142","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/ndt\/gfac242","volume":"38","author":"M Nangaku","year":"2023","unstructured":"Nangaku, M. et al. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. Nephrol. Dial. Transpl. 38, 1204\u20131216 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR143","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/ckj\/sfac143","volume":"15","author":"J Donate-Correa","year":"2022","unstructured":"Donate-Correa, J. et al. Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease. Clin. Kidney J. 15, 2200\u20132213 (2022).","journal-title":"Clin. Kidney J."},{"key":"1117_CR144","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/ndt\/gfh127","volume":"19","author":"YM Chen","year":"2004","unstructured":"Chen, Y. M. et al. Pentoxifylline suppresses renal tumour necrosis factor-\u03b1 and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol. Dial. Transpl. 19, 1106\u20131115 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR145","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000079121","volume":"24","author":"K DiPetrillo","year":"2004","unstructured":"DiPetrillo, K. & Gesek, F. A. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am. J. Nephrol. 24, 352\u2013359 (2004).","journal-title":"Am. J. Nephrol."},{"key":"1117_CR146","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/j.ajkd.2008.05.012","volume":"52","author":"SL Lin","year":"2008","unstructured":"Lin, S. L., Chen, Y. M., Chiang, W. C., Wu, K. D. & Tsai, T. J. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am. J. Kidney Dis. 52, 464\u2013474 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR147","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1681\/ASN.2014010012","volume":"26","author":"JF Navarro-Gonz\u00e1lez","year":"2015","unstructured":"Navarro-Gonz\u00e1lez, J. F. et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J. Am. Soc. Nephrol. 26, 220\u2013229 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/srep17150","volume":"5","author":"KL Kuo","year":"2015","unstructured":"Kuo, K. L. et al. Add-on protective effect of pentoxifylline in advanced chronic kidney disease treated with renin-angiotensin-aldosterone system blockade \u2014 a nationwide database analysis. Sci. Rep. 5, 17150 (2015).","journal-title":"Sci. Rep."},{"key":"1117_CR149","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053019","volume":"11","author":"DJ Leehey","year":"2021","unstructured":"Leehey, D. J. et al. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial. BMJ Open. 11, e053019 (2021).","journal-title":"BMJ Open."},{"key":"1117_CR150","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.ajkd.2025.09.030","volume":"87","author":"DJ Leehey","year":"2026","unstructured":"Leehey, D. J. & Agarwal, R. Is there a role for pentoxifylline in diabetic kidney disease? A mini review. Am. J. Kidney Dis. 87, 835\u2013840 (2026).","journal-title":"Am. J. Kidney Dis."},{"key":"1117_CR151","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR152","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319\u2013328 (2018).","journal-title":"Lancet"},{"key":"1117_CR153","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","volume":"41","author":"PM Ridker","year":"2020","unstructured":"Ridker, P. M., MacFadyen, J. G., Thuren, T. & Libby, P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur. Heart J; 41, 2153\u20132163 (2020).","journal-title":"Eur. Heart J;"},{"key":"1117_CR154","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","volume":"71","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Inhibition of Interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J. Am. Coll. Cardiol. 71, 2405\u20132414 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1117_CR155","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833\u20131842 (2017).","journal-title":"Lancet"},{"key":"1117_CR156","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1681\/ASN.2016040453","volume":"28","author":"KL Nowak","year":"2017","unstructured":"Nowak, K. L. et al. IL-1 inhibition and vascular function in CKD. J. Am. Soc. Nephrol. 28, 971\u2013980 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR157","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060\u20132069 (2021).","journal-title":"Lancet"},{"key":"1117_CR158","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","volume":"11","author":"PM Ridker","year":"2026","unstructured":"Ridker, P. M. et al. Rationale, design, and baseline clinical characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: interleukin-6 inhibition and atherosclerotic event rate reduction. JAMA Cardiol. 11, 89\u201397 (2026).","journal-title":"JAMA Cardiol."},{"key":"1117_CR159","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06118281 (2026)."},{"key":"1117_CR160","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05636176 (2026)."},{"key":"1117_CR161","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06200207 (2026)"},{"key":"1117_CR162","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","volume":"30","author":"GM Chertow","year":"2024","unstructured":"Chertow, G. M. et al. IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat. Med. 30, 2328\u20132336 (2024).","journal-title":"Nat. Med."},{"key":"1117_CR163","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1681\/ASN.0000000654","volume":"36","author":"BL Neuen","year":"2025","unstructured":"Neuen, B. L. et al. Effects of clazakizumab on anemia and iron metabolism in patients with kidney failure. J. Am. Soc. Nephrol. 36, 923\u2013925 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR164","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","volume":"35","author":"PE Pergola","year":"2024","unstructured":"Pergola, P. E. et al. Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3\u20135: an analysis of a randomized trial (RESCUE). J. Am. Soc. Nephrol. 35, 74\u201384 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR165","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05485961 (2026)"},{"key":"1117_CR166","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06362759 (2026)."},{"key":"1117_CR167","doi-asserted-by":"publisher","first-page":"J3","DOI":"10.1093\/eurheartj\/suaa115","volume":"22","author":"TD O\u2019Connell","year":"2020","unstructured":"O\u2019Connell, T. D., Mason, R. P., Budoff, M. J., Navar, A. M. & Shearer, G. C. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. Eur. Heart J. Suppl. 22, J3\u2013J20 (2020).","journal-title":"Eur. Heart J. Suppl."},{"key":"1117_CR168","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1056\/NEJMoa2513032","volume":"394","author":"CE Lok","year":"2026","unstructured":"Lok, C. E. et al. Fish-oil supplementation and cardiovascular events in patients receiving hemodialysis. N. Engl. J. Med. 394, 128\u2013137 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR169","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s44161-026-00807-5","volume":"5","author":"X Xia","year":"2026","unstructured":"Xia, X. et al. Mechanisms and therapeutic potential of colchicine in atherosclerotic cardiovascular disease. Nat. Cardiovasc. Res. 5, 404\u2013422 (2026).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1117_CR170","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR171","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838\u20131847 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR172","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","volume":"392","author":"SS Jolly","year":"2025","unstructured":"Jolly, S. S. et al. Colchicine in acute myocardial infarction. N. Engl. J. Med. 392, 633\u2013642 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR173","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ehjcvp\/pvaf011","volume":"11","author":"C Laudani","year":"2025","unstructured":"Laudani, C., Abbate, A., Angiolillo, D. J. & Galli, M. CLEAR results, cloudy impact: colchicine\u2019s neutral role in ST-segment elevation myocardial infarction. Eur. Heart J. Cardiovasc. Pharmacother. 11, 215\u2013217 (2025).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"1117_CR174","first-page":"843","volume":"13","author":"JC Tardif","year":"2024","unstructured":"Tardif, J. C. & Kouz, S. Efficacy and safety of colchicine and spironolactone after myocardial infarction: the CLEAR-SYNERGY trial in perspective. Eur. Heart J. Acute Cardiovasc. Care 13, 843\u2013844 (2024).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"1117_CR175","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1093\/eurheartj\/ehaf210","volume":"46","author":"MA d\u2019Entremont","year":"2025","unstructured":"d\u2019Entremont, M. A. et al. Colchicine for secondary prevention of vascular events: a meta-analysis of trials. Eur. Heart J. 46, 2564\u201325751 (2025).","journal-title":"Eur. Heart J."},{"key":"1117_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2026.100147","volume":"78","author":"AA Mangoni","year":"2026","unstructured":"Mangoni, A. A., Hulin, J. A. & Tommasi, S. Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases. Pharmacol. Rev. 78, 100147 (2026).","journal-title":"Pharmacol. Rev."},{"key":"1117_CR177","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00296-026-06129-w","volume":"46","author":"Y Fedorchenko","year":"2026","unstructured":"Fedorchenko, Y., Khojakulova, U., Permenov, B. A., Fedorchenko, M. & Usen, A. Cardiometabolic risk and vascular changes in rheumatic diseases. Rheumatol. Int. 46, 93 (2026).","journal-title":"Rheumatol. Int."},{"key":"1117_CR178","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752\u2013762 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR179","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon, D. H. et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann. Intern. Med. 172, 369\u2013380 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1117_CR180","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","volume":"187","author":"M Lamkanfi","year":"2009","unstructured":"Lamkanfi, M. et al. Glyburide inhibits the cryopyrin\/Nalp3 inflammasome. J. Cell Biol. 187, 61\u201370 (2009).","journal-title":"J. Cell Biol."},{"key":"1117_CR181","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cmdc.201700270","volume":"12","author":"JR Hill","year":"2017","unstructured":"Hill, J. R. et al. Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors. ChemMedChem 12, 1449\u20131457 (2017).","journal-title":"ChemMedChem"},{"key":"1117_CR182","doi-asserted-by":"publisher","first-page":"14447","DOI":"10.1021\/acs.jmedchem.3c01370","volume":"66","author":"N Li","year":"2023","unstructured":"Li, N. et al. Recent progress and prospects of small molecules for NLRP3 inflammasome inhibition. J. Med. Chem. 66, 14447\u201314473 (2023).","journal-title":"J. Med. Chem."},{"key":"1117_CR183","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2174\/0929867327666200123093544","volume":"28","author":"M Su","year":"2021","unstructured":"Su, M., Wang, W., Liu, F. & Li, H. Recent progress on the discovery of NLRP3 inhibitors and their therapeutic potential. Curr. Med. Chem. 28, 569\u2013582 (2021).","journal-title":"Curr. Med. Chem."},{"key":"1117_CR184","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"No author group","year":"2024","unstructured":"No author group KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"1117_CR185","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1161\/CIR.0000000000001396","volume":"152","author":"DW Jones","year":"2025","unstructured":"Jones, D. W. et al. AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 152, e114\u2013e218 (2025).","journal-title":"Circulation"},{"key":"1117_CR186","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895\u2013e1032 (2022).","journal-title":"Circulation"},{"key":"1117_CR187","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"P Dandona","year":"2007","unstructured":"Dandona, P., Dhindsa, S., Ghanim, H. & Chaudhuri, A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 21, 20\u201327 (2007).","journal-title":"J. Hum. Hypertens."},{"key":"1117_CR188","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1681\/ASN.2016101066","volume":"28","author":"SD Crowley","year":"2017","unstructured":"Crowley, S. D. & Rudemiller, N. P. Immunologic effects of the renin-angiotensin system. J. Am. Soc. Nephrol. 28, 1350\u20131361 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR189","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","volume":"97","author":"K Awad","year":"2022","unstructured":"Awad, K. et al. Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin. Proc. 97, 1808\u20131823 (2022).","journal-title":"Mayo Clin. Proc."},{"key":"1117_CR190","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/01.CIR.0000153272.48711.B9","volume":"111","author":"S Sola","year":"2005","unstructured":"Sola, S. et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 111, 343\u2013348 (2005).","journal-title":"Circulation"},{"key":"1117_CR191","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00004872-200502000-00027","volume":"23","author":"EA Rosei","year":"2005","unstructured":"Rosei, E. A. et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J. Hypertens. 23, 435\u2013444 (2005).","journal-title":"J. Hypertens."},{"key":"1117_CR192","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1045235","volume":"13","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: a systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 13, 1045235 (2022).","journal-title":"Front. Pharmacol."},{"key":"1117_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim, S. R. et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 11, 2127 (2020).","journal-title":"Nat. Commun."},{"key":"1117_CR194","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","volume":"62","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62, 1154\u20131166 (2019).","journal-title":"Diabetologia"},{"key":"1117_CR195","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara, A. et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 715, 246\u2013255 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"1117_CR196","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 20, 137\u2013149 (2017).","journal-title":"EBioMedicine"},{"key":"1117_CR197","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","volume":"32","author":"Y Birnbaum","year":"2018","unstructured":"Birnbaum, Y., Bajaj, M., Yang, H. C. & Ye, Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. Cardiovasc. Drugs Ther. 32, 135\u2013145 (2018).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"1117_CR198","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R. & Birnbaum, Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31, 119\u2013132 (2017).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"1117_CR199","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054442","volume":"8","author":"U Panchapakesan","year":"2013","unstructured":"Panchapakesan, U. et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS ONE 8, e54442 (2013).","journal-title":"PLoS ONE"},{"key":"1117_CR200","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","volume":"313","author":"L Tang","year":"2017","unstructured":"Tang, L. et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 313, E563\u2013E576 (2017).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1117_CR201","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.dsx.2019.06.028","volume":"13","author":"M Ashrafizadeh","year":"2019","unstructured":"Ashrafizadeh, M., Yaribeygi, H., Atkin, S. L. & Sahebkar, A. Effects of newly introduced antidiabetic drugs on autophagy. Diabetes Metab. Syndr. 13, 2445\u20132449 (2019).","journal-title":"Diabetes Metab. Syndr."},{"key":"1117_CR202","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"No author group","year":"2022","unstructured":"No author group KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1\u2013S127 (2022).","journal-title":"Kidney Int."},{"key":"1117_CR203","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"2024","author":"SD Solomon","year":"2024","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 2024, 1475\u20131485 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR204","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan, M. et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat. Med. 30, 3758\u20133764 (2024).","journal-title":"Nat. Med."},{"key":"1117_CR205","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/S0140-6736(26)01009-3","volume":"407","author":"BL Neuen","year":"2026","unstructured":"Neuen, B. L. et al. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). Lancet 407, 2375\u20132386 (2026).","journal-title":"Lancet"},{"key":"1117_CR206","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","volume":"123","author":"D Fraccarollo","year":"2011","unstructured":"Fraccarollo, D. et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400\u2013408 (2011).","journal-title":"Circulation"},{"key":"1117_CR207","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1125693","volume":"14","author":"R Lv","year":"2023","unstructured":"Lv, R. et al. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front. Endocrinol. 14, 1125693 (2023).","journal-title":"Front. Endocrinol."},{"key":"1117_CR208","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1117_CR209","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 13, 15\u201328 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1117_CR210","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc24-1533","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee, M. M. Y. et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care 48, 846\u2013859 (2025).","journal-title":"Diabetes Care"},{"key":"1117_CR211","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR212","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley, R. E. et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the flow trial. J. Am. Coll. Cardiol. 84, 1615\u20131628 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1117_CR213","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2025","unstructured":"Apperloo, E. M. et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat. Med. 31, 278\u2013285 (2025).","journal-title":"Nat. Med."},{"key":"1117_CR214","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR215","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR216","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.2337\/dc12-2469","volume":"36","author":"A Ceriello","year":"2013","unstructured":"Ceriello, A. et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36, 2346\u20132350 (2013).","journal-title":"Diabetes Care"},{"key":"1117_CR217","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc13-2618","volume":"37","author":"A Ceriello","year":"2014","unstructured":"Ceriello, A. et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 37, 1938\u20131943 (2014).","journal-title":"Diabetes Care"},{"key":"1117_CR218","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","volume":"36","author":"CK Wong","year":"2024","unstructured":"Wong, C. K. et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 36, 130\u2013143 (2024).","journal-title":"Cell Metab."},{"key":"1117_CR219","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris, K. C. et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 105, 132\u2013149 (2024).","journal-title":"Kidney Int."},{"key":"1117_CR220","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/ndt\/gfaf114","volume":"40","author":"DZI Cherney","year":"2025","unstructured":"Cherney, D. Z. I. et al. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol. Dial. Transpl. 40, 2182\u20132192 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1117_CR221","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402, 2077\u20132090 (2023).","journal-title":"Lancet"},{"key":"1117_CR222","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","volume":"389","author":"MN Rheault","year":"2023","unstructured":"Rheault, M. N. et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N. Engl. J. Med. 389, 2436\u20132445 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1117_CR223","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937\u20131947 (2019).","journal-title":"Lancet"},{"key":"1117_CR224","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04724837 (2024)."},{"key":"1117_CR225","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004\u20132017 (2023).","journal-title":"Lancet"},{"key":"1117_CR226","doi-asserted-by":"publisher","first-page":"24297","DOI":"10.1074\/jbc.M109.032524","volume":"284","author":"SJ Wort","year":"2009","unstructured":"Wort, S. J. et al. Synergistic induction of endothelin-1 by tumor necrosis factor \u03b1 and interferon \u03b3 is due to enhanced NF-\u03baB binding and histone acetylation at specific \u03baB sites. J. Biol. Chem. 284, 24297\u201324305 (2009).","journal-title":"J. Biol. Chem."},{"key":"1117_CR227","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ncpneph0891","volume":"4","author":"M Barton","year":"2008","unstructured":"Barton, M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat. Clin. Pract. Nephrol. 4, 490\u2013501 (2008).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"1117_CR228","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/jpet.111.178988","volume":"338","author":"MA Saleh","year":"2011","unstructured":"Saleh, M. A., Pollock, J. S. & Pollock, D. M. Distinct actions of endothelin A-selective versus combined endothelin A\/B receptor antagonists in early diabetic kidney disease. J. Pharmacol. Exp. Ther. 338, 263\u2013270 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1117_CR229","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.110.156570","volume":"56","author":"MA Saleh","year":"2010","unstructured":"Saleh, M. A., Boesen, E. I., Pollock, J. S., Savin, V. J. & Pollock, D. M. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 56, 942\u2013949 (2010).","journal-title":"Hypertension"},{"key":"1117_CR230","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1042\/CS20210549","volume":"135","author":"O Rivera-Gonzalez","year":"2021","unstructured":"Rivera-Gonzalez, O., Wilson, N. A., Coats, L. E., Taylor, E. B. & Speed, J. S. Endothelin receptor antagonism improves glucose handling, dyslipidemia, and adipose tissue inflammation in obese mice. Clin. Sci. 135, 1773\u20131789 (2021).","journal-title":"Clin. Sci."},{"key":"1117_CR231","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0735-1097(03)00846-5","volume":"42","author":"KK Koh","year":"2003","unstructured":"Koh, K. K. et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J. Am. Coll. Cardiol. 42, 905\u2013910 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1117_CR232","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3317\/jraas.2001.011","volume":"2","author":"A Sonmez","year":"2001","unstructured":"Sonmez, A. et al. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. J. Renin Angiotensin Aldosterone Syst. 2, 112\u2013116 (2001).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"1117_CR233","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/00019501-200510000-00002","volume":"16","author":"RG Lopez Santi","year":"2005","unstructured":"Lopez Santi, R. G. et al. Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES study. Coron. Artery Dis. 16, 423\u2013429 (2005).","journal-title":"Coron. Artery Dis."},{"key":"1117_CR234","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1161\/01.CIR.0000143085.86697.13","volume":"110","author":"KK Koh","year":"2004","unstructured":"Koh, K. K. et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110, 3687\u20133692 (2004).","journal-title":"Circulation"},{"key":"1117_CR235","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2004.03.065","volume":"44","author":"B Schieffer","year":"2004","unstructured":"Schieffer, B. et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J. Am. Coll. Cardiol. 44, 362\u2013368 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1117_CR236","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1681\/ASN.2011030287","volume":"23","author":"JL Gamboa","year":"2012","unstructured":"Gamboa, J. L. et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J. Am. Soc. Nephrol. 23, 334\u2013342 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1117_CR237","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061457","volume":"10","author":"J Xu","year":"2021","unstructured":"Xu, J., Kitada, M., Ogura, Y., Liu, H. & Koya, D. Dapagliflozin restores impaired autophagy and suppresses inflammation in high glucose-treated HK-2 Cells. Cells 10, 1457 (2021).","journal-title":"Cells"},{"key":"1117_CR238","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers, C. C. J. et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes. Metab. 20, 1988\u20131993 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1117_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107773","volume":"96","author":"Y Niu","year":"2021","unstructured":"Niu, Y. et al. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: a potential COVID-19 treatment. Int. Immunopharmacol. 96, 107773 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"1117_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71599-2","volume":"10","author":"R Hasan","year":"2020","unstructured":"Hasan, R. et al. Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model. Sci. Rep. 10, 14659 (2020).","journal-title":"Sci. Rep."},{"key":"1117_CR241","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","volume":"64","author":"T Sen","year":"2021","unstructured":"Sen, T. et al. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia 64, 2147\u20132158 (2021).","journal-title":"Diabetologia"},{"key":"1117_CR242","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9944880","volume":"2021","author":"N Lee","year":"2021","unstructured":"Lee, N. et al. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J. Immunol. Res. 2021, 9944880 (2021).","journal-title":"J. Immunol. Res."},{"key":"1117_CR243","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-018-0395-5","volume":"10","author":"S Hattori","year":"2018","unstructured":"Hattori, S. Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol. Metab. Syndr. 10, 93 (2018).","journal-title":"Diabetol. Metab. Syndr."},{"key":"1117_CR244","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134458","volume":"12","author":"M Gotzmann","year":"2023","unstructured":"Gotzmann, M. et al. Empagliflozin reduces interleukin-6 levels in patients with heart failure. J. Clin. Med. 12, 4458 (2023).","journal-title":"J. Clin. Med."},{"key":"1117_CR245","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04289-z","volume":"79","author":"R La Grotta","year":"2022","unstructured":"La Grotta, R. et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol. Life Sci. 79, 273 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"1117_CR246","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune, J. et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71, 599\u2013608 (2018).","journal-title":"Hypertension"},{"key":"1117_CR247","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal, J. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344\u20131355 (2018).","journal-title":"Kidney Int."},{"key":"1117_CR248","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0329965","volume":"20","author":"J Song","year":"2025","unstructured":"Song, J. et al. Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease. PLoS ONE 20, e0329965 (2025).","journal-title":"PLoS ONE"},{"key":"1117_CR249","doi-asserted-by":"publisher","unstructured":"Tuttle, K. R. et al. Mechanistic effects of semaglutide on kidney disease in type 2 diabetes: the REMODEL trial. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.2025fdqxb4qe (2025).","DOI":"10.1681\/ASN.2025fdqxb4qe"},{"key":"1117_CR250","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1210\/jc.2011-1508","volume":"97","author":"A Chaudhuri","year":"2012","unstructured":"Chaudhuri, A. et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198\u2013207 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1117_CR251","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCRESAHA.116.301135","volume":"116","author":"S Zimmer","year":"2015","unstructured":"Zimmer, S., Grebe, A. & Latz, E. Danger signaling in atherosclerosis. Circ. Res. 116, 323\u2013340 (2015).","journal-title":"Circ. Res."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01117-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01117-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01117-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:38:53Z","timestamp":1792096733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01117-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":251,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01117-6","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"6 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.R.T has received investigator-initiated grant support from Benaroya Research Institute, Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), the Doris Duke Charitable Foundation, Travere, Bayer, and Otsuka; consultancy fees from Alnylam, AstraZeneca, Boehringer Ingelheim, Bayer, Glaxo Smith Kline, Lilly, Novo Nordisk, Otsuka, ProKidney and Roche; and speaker fees from Astra Zeneca, Novo Nordisk, Boehringer Ingelheim, Bayer and Travere. K.R.T. is also chair of the data safety monitoring boards for the National Institute of Diabetes and Digestive and Kidney Disease, and George Clinical Institute, and a member of the data safety monitoring board for AstraZeneca. R.Z.A. has received research support from Benaroya Research Institute, Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), the Doris Duke Charitable Foundation, Travere, Bayer, Otsuka, Novartis, Boehringer Ingelheim, AstraZeneca, Novo Nordisk, The George Institute for Global Health, CareDx and KBP BioSciences; and personal fees from Boehringer Ingelheim, Bayer Pharmaceuticals and Eli Lilly. J.J.C. reports funding unrelated to this work to Karolinska Institutet from AstraZeneca, Boehringer Ingelheim, Vifor Pharma, NovoNordisk and MSD, as well as personal fees from Fresenius Kabi and Laboratorios Columbia. A.M.N. has received honoraria for consulting from Amgen, Arrowhead, AstraZeneca, Bayer, Eli Lilly, Esperion, Janssen, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Roche, Silence Therapeutics and research support to her institution from Amgen and Esperion. B.L.N. has received consulting fees from AstraZeneca, Alexion, Bayer, Boehringer Ingelheim, Medscape, Cambridge Healthcare Research; speaking honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, the Limbic, Cornerstone Medical Education and Travere Therapeutics; travel support from Bayer, Boehringer Ingelheim and Novo Nordisk (with all payments made to The George Institute for Global Health). V.P. has received honoraria for steering committee, data monitoring committee or advisory board roles or for scientific presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, GlaxoSmithKline, Janssen, Novo Nordisk, Novartis, Otsuka, Travere, Tricida and UptoDate; and is a Board Director for George Clinical, St. Vincents Health Australia and several independent medical research institutes. P.R. has received institutional research grant support from Novarti, Novo Nordisk, Kowa, Amarin, Pfizer, Bristol Myers Squibb and Esperion; has served as a consultant to Novartis, Novo Nordisk, Agepha, Ardelyx, CSL Behring, Tourmaline Bio, Nodthera, Cardio Therapeutics, Bio Age, AstraZeneca, Civi Biopharm, Glaxo Smith Kline, SOCAR, Eli Lilly, New Amsterdam, HeartFlow, Caristo, Boehringer-Ingelheim and Cardiol Therapeutics; has minority shareholder equity positions in Uppton, Bitteroot Bio and Angiowave; and receives compensation for service on the Leducq Foundation Advisory Board, Paris, France. N.M. has given lectures for Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly and Novo Nordisk; has received unrestricted research grants from Boehringer Ingelheim; has served as an adviser for Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Novo Nordisk; and served in a trial leadership capacity for Boehringer Ingelheim and Novo Nordisk. N.M. declines all personal compensation from pharma or device companies. P.M.R. has received institutional research grant support from Kowa, Novartis, Amarin, Pfizer, Esperion and Novo Nordisk; during the past 5 years has served as a consultant to Novartis, Flame, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Civi Biopharm, Glaxo Smith Kline, SOCAR, Novo Nordisk, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer-Ingelheim, RTI, Zomagen, Cytokinetics, Horizon Therapeutics and Cardio Therapeutics; has minority shareholder equity positions in Uppton, Bitteroot Bio and Angiowave; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris, France, and the Baim Institute (Boston, MA, USA). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}